Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VRT 106

Next Previous
Drug Profile

VRT 106

Alternative Names: M1 c6v1; Recombinant oncolytic virus M1 - Guangzhou Virotech Pharmaceutical; VRT-106

Latest Information Update: 26 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangzhou Virotech Pharmaceutical
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Pancreatic cancer
  • Phase I Solid tumours

Most Recent Events

  • 12 Mar 2025 Xiangya Hospital of Central South University plans a phase I/II trial for Pancreatic Cancer (Late stage disease, Metastatic disease, First line therapy, Combination therapy, Unresectable/Inoperable) in China (IV) in March 2025 (NCT06866977)
  • 13 Feb 2025 Guangzhou Virotech Pharmaceutical plans a phase-I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in March 2025 (IV), (NCT06826313),
  • 12 Dec 2024 Phase-I/II clinical trials in Pancreatic cancer (First-line therapy, Combination therapy) in China (IV) (NCT06758544)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top